According to a new BioCrossroads report, in 2024, Indiana was the largest national exporter of life science products and the industry generated $99 billion in economic activity.
Read MoreThe European Medicines Agency, citing the potentially dangerous risk of brain swelling and hemorrhage, rejected Eli Lilly and Co.’s new Alzheimer’s disease drug Kisunla.
Read MoreNewsweek’s annual list of “Most Trustworthy Companies
in America” has been published, with 13 Hoosier businesses appearing.
Eli Lilly and Co. is moving ahead with a $10 million solar panel installation project on their two Indianapolis corporate campuses.
Read MoreOver a decade ago, Eli Lilly and Co. was struggling.
Read MoreGov. Eric Holcomb on Wednesday defended his signing of a near-total abortion ban this month and brushed off fears of business and talent attraction consequences in the wake of ominous statements from major homegrown employers.
Read MoreBy DAN MCGOWAN Writer/Reporter, Inside Indiana Business A potential rheumatoid arthritis treatment being co-developed by Indianapolis-based Eli Lilly and Co. and Incyte Corp. continues to return positive results in late-stage testing. In a recent phase-three global study, Lilly says baricitinib met its primary endpoint. The results have been published in … Read More
By ANDY OBER Assistant Managing Editor InsideIndianaBusiness INDIANAPOLIS — The U.S. Food and Drug Administration has approved a type 2 diabetes treatment from Indianapolis-based Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals Inc. Synjardy was also approved earlier this year by the European Medicines Agency. Lilly says Synjardy is the … Read More
Eli Lilly and Company (NYSE: LLY) yesterday announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry. The transaction, first announced on April 22, has received clearance under the Hart-Scott-Rodino Antitrust Improvements … Read More
Eli Lilly and Company (NYSE: LLY) has received its third US Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). Specifically, CYRAMZA is now also indicated in combination with docetaxel, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients … Read More
Eli Lilly and Company (NYSE: LLY) and AstraZeneca yesterday announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. AZD3293, also known as LY3314814, has been shown … Read More
